Kornimate/medical-research-clean huggingface dataset:
a study of the effects of peitc on oral cells with mutant p53

Conditions: Oral Cancer

Summary: the aim of this clinical trial is to examine the effects of phenethyl isothiocyanate (peitc), a compound derived from cruciferous vegetables, on oral cells with mutant p53. the p53 protein's normal (wild-type) function within cells is to act as a tumor suppressor, or anti-cancer protein. when mutated, the p53 protein not only no longer executes the functions of a tumor suppressor, and it can gain functions as a pro-cancer protein.22 the proposed clinical trial will utilize oral cells collected from subjects who are heavy smokers. since the subjects are regularly exposed to mutagenic chemicals it is the thought that their oral cells will contain measurable levels of mutant p53. the participants will consume watercress juice, which is rich in peitc (see figure 1). previous studies in the laboratory showed peitc selectively depletes mutant p53, and not wild type p53, in cell culture. our hypothesis is that the itc in the watercress juice will lead to the depletion of mutant p53 within the oral cells. this depletion could lead to a possible clinical application of this compound, such as chemopreventives or oncologic treatments of individuals with oral cancers.


Eligibility criteria:
inclusion criteria: * heavy smoker * between the ages of 20 and 65 * must be able to show proof of citizenship or residency of the united states * able to sign and understand a standard consent form exclusion criteria: * pregnant or breast-feeding * having any of the following medical conditions: * leukoplakia * oral lesions * cancer * any oral disease that causes sores, ulcerations, irritations, etc. * stomach or intestinal ulcers * ibs (irritable bowel syndrome) * kidney disease * allergies to watercress or other cruciferous vegetables * strict vegetarians or vegans * religious consumers of watercress or other cruciferous vegetable juices * on any of the following medications: * chlorzoxazone (parafon forte, paraflex) * lithium * water pills/diuretics (thiazide or lasix) * warfarin (coumadin) * vitamin k supplements * h2 acid blocker (zantac, pepcid, axid, tagamet) * proton pump inhibitor (prevacid) * digoxin * antibiotics * diabetic medications (insulin) * inhaled bronchodilator * oral steroids (prednisone, medrol) * inhaled steroids (flonase) * raloxifene or tamoxifen * thyroid hormone replacement

Keywords: mutant p53 watercress phenethyl isothyocyanate oral cells of smokers
effect of a servo-control system on heat loss in very low birth weight infants at birth

Conditions: Neonatal Hypothermia

Summary: hypothermia in preterm infants during the immediate postnatal phase is associated with morbidity and mortality and remains an unresolved, worldwide challenge. a list of interventions, including adequate room temperature, use of infant warmers, polyethylene bags/wrap, pre-heated mattresses, caps and heated and humidified gases, to prevent thermal loss at birth in very preterm infants has been recommended, but a certain percentage of very preterm infants are hypothermic at the time of the neonatal intensive care unit (nicu) admission suggesting that further measures are needed. the thermal servo-controlled systems are routinely used in the nicu to accurately manage the patients' temperature, but their role during the immediate postnatal phase has not been previously assessed. we hypothesized that using a thermal servo-control system at delivery could prevent heat loss during this delicate phase and increase the percentage of very low birth weight infants (vlbwi) in the normal thermal range (temperature 36.5-37.5°c) at nicu admission. the aim of this study will be to compare two modes of thermal management (with and without the use of a thermal servo-controlled system) for preventing heat loss at birth in vlbwi infants.


Eligibility criteria:
inclusion criteria: 1. estimated birth weight \<1500 g and/or gestational age \<30+6 weeks (and) 2. inborn (and) 3. parental consent exclusion criteria: 1. major congenital malformations (i.e. cardiac disease, defects of abdominal wall, ...); 2. outborn; 3. parental refusal to participate to the study.
clinic-based ames treatment of stroke

Conditions: Stroke; Cerebrovascular Accident

Summary: this study investigates whether assisted movement with biofeedback and muscle vibration applied to the lower limb reduces impairment and improves gait.

the hypothesis of this study is that chronic stroke survivors, more than one year post-stroke, with a motor problems in the lower extremity will be able to walk and move the affected leg better after 30 treatments with a new robotic therapy device, the ames device. the device rotates the ankle while vibrators stimulate the tendons attached to muscles that move the ankle. testing will be done before, during and after the treatments to determine response to the therapy.

Eligibility criteria:
inclusion criteria: * at least 12 months post-stroke * cognitively and behaviorally capable of complying with the regimen * functioning proprioception * less than 50% of normal strength in the affected ankle, but able to stand with or without assistive devices exclusion criteria: * fractures of treated limb resulting in loss of range of motion * spinal cord injury * deep vein thrombosis * peripheral nerve injury or neuropathy in the limb affected with motor disability * osteoarthritis limiting range of motion * skin condition not tolerant of device * progressive neurodegenerative disorder * uncontrolled seizure disorder * botox treatment within the last 5 months * baclofen pump

Keywords: stroke rehabilitation robotics
soreness after deep dry needling of one latent myofascial trigger point

Conditions: Pain After Dry Needling

Summary: pain after dry needling or injection in the muscle is a frequent secondary effect in the treatment of myofascial pain syndrome. in this trial pain and sensitivity will be assessed during a 72 hours follow up period. factors that may contribute to higher levels of pain or sensitivity will be evaluated.


Eligibility criteria:
inclusion criteria: the latent mtrp diagnosis was based upon the following criteria:10 1. presence of a palpable taut band in the muscle 2. presence of a hypersensitive tender spot in the taut band 3. palpable or visible local twitch response with snapping palpation of the tout band 4. referred pain elicitation in response to compression. exclusion criteria: 1. presence of coagulation disorders 2. neck or facial pain 3. previous application of a dry needling technique 4. mtrp therapy in head or neck within the previous 3 months 5. fibromyalgia 6. an insurmountable fear of needles as a reason of refusing the treatment 7. history of surgery in the head or neck area.
efficacy and mechanism of tccrp in patients with chronic coronary syndrome under fusion cardiac rehabilitation model

Conditions: Coronary Heart Disease; Chronic Coronary Syndrome

Summary: this study is a prospective, multi-center, randomized controlled clinical study. it developed an innovative tai chi cardiac rehabilitation program (tccrp) for patients with chronic coronary syndrome (ccs) and evaluated the efficacy, acceptability and safety of tccrp on patients with ccs in order to explore the possible mechanism of its feasibility.

this study is a prospective, multi-center, randomized controlled clinical trial of 100 participants with chronic coronary syndrome (ccs) that compares tai chi cardiac rehabilitation program (tccrp) with conventional exercise rehabilitation programs (cerp), with an allocation ratio of 1:1. a total of 6 months study period, including 1 month in-hospital rehabilitation, 2 months home-based rehabilitation and 3 months follow-up. the main outcome indicators were measured at baseline, 1 month, 3 months and 6 months. the secondary outcome measures will be measured at baseline and at 3 months.

Eligibility criteria:
inclusion criteria 1. male or non-pregnant women aged from 18 to 80 years; 2. patients who met the stable angina pectoris in accordance with coronary heart disease; 3. nyha class ι, π or ш; 4. participants were able to understand the purpose of clinical trials and voluntarily participate and sign informed consent. exclusion criteria 1. acute myocardial infarction (ami) within 2 weeks; 2. severe aortic stenosis; 3. hypertrophic cardiomyopathy; 4. severe valvular heart disease; 5. malignant tachyarrhythmia; 6. the patient compliance was poor and the clinical trial could not be completed according to the requirements. 7. combined exercise can cause deterioration of the nervous system, motor system disease, or rheumatic disease. 8. in the past 3 months, those who regularly practice tai chi; 9. patients with gastrointestinal diseases, infectious diseases, renal insufficiency, and a history of gastrointestinal surgery within one year

Keywords: tai chi cardiac rehabilitation chronic coronary syndrome safety effectiveness randomized controlled trial fusion cardiac rehabilitation model
effect of celecoxib on perioperative inflammatory response in colon cancer

Conditions: Colorectal Cancer; Colon Cancer

Summary: the proposed study aims to investigate how the administration of a drug known to reduce inflammation in humans, celecoxib, will effect the peri-operative inflammatory response of a patient undergoing primary tumor resection surgery for colon cancer. the proposed project is an exploratory study, and will use data from blood samples and tumor samples to attempt to elucidate the immune and inflammatory response in colon cancer patients undergoing primary resection of their tumors.

this study is the first to assess the perioperative time course of systemic inflammation and immunity in colon cancer patients and evaluate the effect of anti-inflammatory treatment with celecoxib on this response. in addition, evaluation of the effect of short-term preoperative administration of celecoxib on tumor immunogenicity will help us to understand how tumor-enhancing inflammation and anti-tumor immunity can be differentially affected by cox-2 inhibitors. the knowledge gained as a result of this research will help us to set up the infrastructure for a method to monitor the immunoinflammatory status of colon cancer patients with a longer term goal of designing interventions to suppress tumor-enhancing inflammation and vitalize anti-tumor immunity in the perioperative period. the long-term objective is to use these novel tools in order to improve cancer-specific survival in patients with colon cancer after primary tumor resection.

Eligibility criteria:
inclusion criteria: - colon cancer patients with no evidence of metastasis in distant organs (i.e., tnm stage i-iii), who are * between 18 and 75 years old, * have a body mass index (bmi) between 18 and 35 kg/m\^2, * and are eligible for laparoscopically-assisted colectomy for primary tumor resection. * patients must have the ability to understand and the willingness to sign a written informed consent document. exclusion criteria: - a history of allergic-type reactions to celecoxib or sulphonamides, * a history of asthma, skin reactions or other allergic reactions to aspirin or other nsaids, * a history of thromboembolic event (cerebrovascular accident, transient ischemic attack, * unstable angina, myocardial infarction, deep vein thrombosis, or pulmonary embolism), * renal insufficiency (defined by a serum creatinine level \> 1.5 mg/dl or blood urea nitrogen level \> 22 mg/dl), * active gastrointestinal bleeding in the 60 days before surgery, * alcohol or drug abuse, and * previous chemotherapy or abdominal/pelvic radiation therapy. * after randomization, other exclusion criteria will include a surgical procedure longer than 6 h, inability to extubate the trachea within 4 h after operation, evidence of a new postoperative myocardial infarction, abnormal postoperative mental status or any new neurologic deficit, significant postoperative bleeding (with a hemoglobin level \< 7.5 g/dl), requiring blood transfusion, or a urine output of less than 30 ml/h.
evidence based treatment - heart failure (evita-hf)

Conditions: Heart Failure

Summary: evita should function as an idea supplier and should coordinate possible future studies. other important tasks of the register are: (i) the establishment of recommendations for an optimal medicinal therapy (omt) as well as for icd- and crt-treatment; (ii) the establishment of quality assurance measures, including monitoring of new therapy.

cardiac insufficiency is the main or secondary diagnosis of 10% of all hospitalised patients. due to the age-structure of the population and to the increased life expectancy after myocardial infarction prevalence is increasing. even though prognosis in patients with established heart failure has been improved it remains serious, with an average survival rate of 50% after 4 years. approximately 2% of all expenses in health care are caused by cardiac insufficiency, the most expensive being the hospitalization phase. the rehospitalisation rate after the first hospital stay is 50% within 6 months. by optimal, guideline-adjusted therapy during hospital- and post-hospital-stay the rehospitalisation rate could be reduced by 50%. but our knowledge concerning therapies is based on study results, which are generated with selected patients under controlled study conditions. thus it is necessary to collect data on the development of therapy, the successes as well as the complications in clinical everyday life. results concerning the quality of therapies are required and measures are needed that will contribute to quality assurance and improvement. due to these reasons evita was initiated with the following objectives, aims, structure, and organization form: the register will not substitute randomized, controlled, multi-center clinical trials (rct) that have a defined prospective research question. such randomized studies investigate the "efficacy" of a therapy, i.e. a clinical effect under experimental conditions. in contrast, registers investigate the transferability of rct results to the daily routine within hospital, the so called "effectiveness". both study types are complementary and are needed for a judgment of the clinical efficiency as well as of security aspects and possible adverse reactions. furthermore evita should function as an idea supplier and should coordinate possible future studies. other important tasks of the register are: (i) the establishment of recommendations for an optimal medicinal therapy (omt) as well as for icd- and crt-treatment; (ii) the establishment of quality assurance measures, including monitoring of new therapy. every 6 months each study center receives a complete overview concerning the centers own data in comparison with the data supplied by other centers.

Eligibility criteria:
inclusion criteria: * chronical heart failure * ef ≤ 40 % exclusion criteria: * no informed consent

Keywords: heart failure
meningiomas and treatment with cyproterone acetate or progestin

Conditions: Meningioma

Summary: investigators observe an increase risk of meningioma in patient treated by cyproterone acetate or other form of progestin. investigatorsdiscribe caractéristics of meningioma and treatement of the patients follow up in chru of brest

retrospective study in chru of brest, the investigators selected patient with history of méningioma and treated by cyproterone acetate, chlormadinone acetate and nomegestrol acetate essentially the investigators excluded patient with risk factor of meningioma added at hormonal treatment exposition the investigators discribe the caractéristique of patients: age, sex, duration of the treatment, the caractéristique of the meningioma: localization, grade, hormonal receptors, treatment by surgery or radiotherapy and changing after discontinuation of treatment

Eligibility criteria:
inclusion criteria: * minimum 18 years * medical follow up in chru of brest * treated by cyproterone acetate and/or chlormadinone acetate nomegestrol acetate, progesterone , dydrogesterone promegestone , norethisterone, levonorgestrel , oestroprogestogenic contraception * meningioma after treatement by progestin or cyproterone acetate exclusion criteria: * history ofbreast cancer * history of cerebral radiotherapy * history of neurofibromatosis * meningioma before treatement by progestin or cyproterone acetate * minor patient

Keywords: meningioma, progestin, cyproterone acetate
late in-the-bag intraocular lens dislocation surgery

Conditions: Intraocular Lens Dislocation

Summary: overall aim of the study is to compare the safety and efficacy of two different surgical methods to treat late in-the-bag intraocular lens dislocation.

cataract is a condition of unclear lens that cause poor vision. the only treatment is surgery where the blurred biological lens is replaced with an artificial clear lens (iol). most people who operate achieve full vision. nevertheless, serious complications may occasionally occur, and one of these is dislocation of the entire complex with iol and lens capsule. this requires surgical treatment. in this study the investigators want to compare two different surgical methods used in late dislocation of iol inside the capsule after cataract surgery. patients will be randomly affiliated to either the suturing of existing iol / capsule complex, or lens exchange to an iol fixed to the iris. the focus of the trial will be especially on complications and other eye changes in the early stages of surgery. today, little data is available on these topics, and the investigators believe that new knowledge can bring us closer to a response to preferred operating techniques and an optimal drug drop regime for the patient group.

Eligibility criteria:
inclusion criteria: * iol inside the capsule ("in-the-bag") * late dislocation (more than 6 months after cataract surgery) * iol visible in the pupillary area in the supine position and hence possible to perform surgery with an anterior approach * eligibility for both operation methods * ability to cooperate fairly well during the examinations * willing to participate in the study, e.g. willingness to participate at all control visits exclusion criteria: * iol designs that cannot be repositioned with a suture loop, such as plate-haptic iols without holes in the peripheral part * eyes with especially thin sclera * active uveitis or pronounced iris pathology * eyes with previously performed descemet's stripping automated endothelial keratoplasty (dsaek) * totally dislocated iol into the posterior segment of the eye requiring pars plana vitrectomy * eyes that prior to cataract extraction had a subluxated lens in need of surgery with a cionni capsular tension ring (e.g. patients with marfan syndrome and ectopia lentis) * cases requiring a change in refraction. risk of severe anisometropia * patients unable to lie in supine position for surgery in local anesthesia, e.g. severe chronic obstructive pulmonary disease and severe heart failure * patients using anticoagulants that cannot be discontinued for patients with dislocated iols in both eyes during the study period, only the first operated eye will be included. patients without prospects of improvement in vision will be excluded.

Keywords: iol dislocation cataract cataract surgery scleral suturing verisyse iris-claw late in-the-bag iol dislocation
ketogenic diet and its multiple effects on obesity

Conditions: Obesity

Summary: the prevalence of obesity and metabolic disturbances is worryingly increasing worldwide, therefore the study of their pathophysiology is extremely important to find new strategies for their treatment. obesity has a strong impact not only on the metabolism of the patients, but also may impact hormonal, inflammatory and immune profile, and profoundly influence the daily life of the patients. weight loss may determine an amelioration of these parameters, but the impact of the diet composition aimed to weight loss on them has not been profoundly studied yet. the aim of our research project is to study the effects of a ketogenic diet in comparison with an isocaloric balanced diet on weight loss and anthropometric parameters, quality of life, hormone profile, sleep, sexual function, circadian rhythm, inflammatory and immunological parameters in obese patients.


Eligibility criteria:
inclusion criteria: * age between 18 and 65 years * bmi≥ 30 kg/m2 exclusion criteria: * type 1 diabetes mellitus and latent autoimmune diabetes in adults * β-cell failure in type 2 diabetes mellitus * use of sodium/glucose cotransporter 2 (sglt2) inhibitors * pregnancy and breastfeeding * kidney failure and moderate-to-severe chronic kidney disease * liver failure * heart failure (nyha iii-iv) * respiratory failure * unstable angina, stroke or myocardial infarction in the last 12 months * cardiac arrhythmias * eating disorders and other severe mental illnesses, alcohol and substance abuse * active/severe infections * planned elective surgery or invasive procedures * rare disorders: porphyria, carnitine deficiency, carnitine palmitoyltransferase deficiency, carnitine-acylcarnitine translocase deficiency, mitochondrial fatty acid β-oxidation disorders, pyruvate carboxylase deficiency

Keywords: obesity metabolism circadian rhythm sleep quality of life balanced diet ketogenic diet immune profile
impact of sequential chemotherapy on young patients breast cancer treated fertility

Conditions: Breast Cancer; Fertility

Summary: breast cancer affect around 52 000 women in france each year. amongst them, 7% are less than 40 years old and 2% are in between 25 and 35 years old. significant therapeutic advances have improved the prognostic of these patients. they will all most likely to received chemotherapy. despite the fact that chemotherapy has many side effects, these women do question the impact of the treatment on their ability to procreate. on 06/08/04 law basis, each patient is allowed to preserve gametes or germinal tissues when medical care potentially affect fertility. functional evaluation of ovarian reserve could help comprehend new chemotherapy protocols, provide fertility information, and help individualize fertility preservation supports. principal objective is to ensure the absence of ovarian stimulation's side effects and assess chemotherapy effects on child carrying potential.


Eligibility criteria:
inclusion criteria: * 18 ≤ age \< 38 * breast cancer histologically proved * under the control of an adjuvant chemotherapy or neo adjuvant chemotherapy * verbal agreement given exclusion criteria: * age ≥ 38 * metastatic breast cancer * non able to follow the design of the study (geographic, social or psychological reasons)

Keywords: breast cancer fertility